Evidence map›Paper›PMID 28408622›Full record

ArticleThe oncologist2017

A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.

Katsuhiro Miura, Jun Konishi, Takaaki Miyake, Masanori Makita, Atsuko Hojo, Yasufumi Masaki, Masatoshi Uno, Jun Ozaki, Chikamasa Yoshida, Daigo Niiya and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 17 institutions in 1 country.

Katsuhiro MiuraDepartment of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan miura.katsuhiro@nihon-u.ac.jp.
Jun KonishiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Takaaki MiyakeDepartment of Oncology/Hematology, Shimane University Hospital, Shimane, Japan.
Masanori MakitaDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Atsuko HojoDivision of Hematology and Oncology, Kasukabe Medical Center, Saitama, Japan.
Yasufumi MasakiDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Masatoshi UnoDivision of Internal Medicine, Kaneda Hospital, Okayama, Japan.
Jun OzakiDepartment of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan.
Chikamasa YoshidaDepartment of Hematology, National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan.
Daigo NiiyaDepartment of Hematology, Okayama Rosai Hospital, Okayama, Japan.
Koichi KitazumeDepartment of Hematology, Showa General Hospital, Tokyo, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
Rika SakaiDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Tomofumi YanoDepartment of Hematology, Okayama Rosai Hospital, Okayama, Japan.
Kazuhiko YamamotoDepartment of Hematology, Okayama City Hospital, Okayama, Japan.
Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Yasushi HiramatsuDepartment of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
Kazutoshi AoyamaDepartment of Hematology, Chugoku Central Hospital, Hiroshima, Japan.
Hideki TsujimuraDivision of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
Jun MurakamiThe Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
Yoshihiro HattaDepartment of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
Masatoshi KannoOncology Center, Nara Medical University Hospital, Nara, Japan.
National Hospital Organization · JPNihon University · JPOkayama Medical Center · JPOkayama Rosai Hospital · JPChiba Cancer Center · JPChugoku Central Hospital · JPHimeji Red Cross Hospital · JPKanagawa Cancer CenterKanazawa Medical University · JPNara Medical University Hospital · JPNiigata University · JPOkayama Prefecture · JPOkayama University · JPShimane University Hospital · JPShowa General Hospital · JPToyama Prefectural Central Hospital · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDecision-making models for elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) are in great demand. PATIENTS AND

methodsThe Society of Lymphoma Treatment in Japan (SoLT-J), in collaboration with the West-Japan Hematology and Oncology Group (West-JHOG), collected and retrospectively analyzed the clinical records of ≥65-year-old patients with DLBCL treated with R-CHOP from 19 sites across Japan to build an algorithm that can stratify adherence to R-CHOP.

resultsA total of 836 patients with a median age of 74 years (range, 65-96 years) were analyzed. In the SoLT-J cohort (

conclusionThe ACA index has the ability to stratify the prognosis, tolerability to cytotoxic drugs, and adherence to treatment of elderly patients with DLBCL treated with R-CHOP.

Indexed as

Geriatric AssessmentPrognosisAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsComorbidityCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Administration ScheduleDrug-Related Side Effects and Adverse ReactionsFemaleHumansHypoalbuminemiaJapanAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineComorbidityDiffuse large B‐cell lymphomaGeriatric assessmentHypoalbuminemiaPersonalized medicineR‐CHOP chemotherapy

Identifiers

PMID28408622
PMCPMC5423505
OpenAlexW2606893633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.